Scientific article

Advances in therapies for pediatric pulmonary arterial hypertension

Published inExpert review of respiratory medicine, vol. 3, no. 3, p. 265-282
Publication date2009

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressive obliteration of the pulmonary vasculature, leading to right heart failure and death if left untreated. Prior to the current treatment era, pulmonary hypertension carried a poor prognosis with a high mortality rate, but its prognosis has changed over the past decades in relation to new therapeutic agents. Nevertheless, pulmonary hypertension continues to be a serious condition, which is extremely challenging to manage. The data in children are often limited owing to the small number of patients, and extrapolation from adults to children is not straightforward. While none of these new therapeutic agents have been specifically approved for children, there is evidence that each can appropriately benefit the PAH child. We review the current understanding of pediatric pulmonary hypertension, classification, diagnostic evaluation and available treatment. A description of targeted pharmacological therapy and new treatments in children is outlined.

Citation (ISO format)
TISSOT-DAGUETTE, Cécile, BEGHETTI, Maurice. Advances in therapies for pediatric pulmonary arterial hypertension. In: Expert review of respiratory medicine, 2009, vol. 3, n° 3, p. 265–282. doi: 10.1586/ers.09.16
Main files (1)
Article (Published version)
ISSN of the journal1747-6348

Technical informations

Creation10/07/2014 3:20:00 PM
First validation10/07/2014 3:20:00 PM
Update time03/14/2023 10:30:52 PM
Status update03/14/2023 10:30:52 PM
Last indexation10/18/2023 9:09:20 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack